Maynard Um
-
-
-
-
-
-
-
Taysha Gene Therapies doses first patient in Rett syndrome pivotal trial
-
-
-
-
-
-
-
Raymond James Starts Taysha Gene Therapies (TSHA) at Strong Buy
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) PT Raised to $14 at Canaccord Genuity
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Taysha Gene Therapies (TSHA)
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Taysha Gene Therapies (TSHA)
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in REVEAL Phase 1/2 Trials
396,379 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

